文献速递泌尿生殖MR

TARGET评分用于MRI检测HIFU半消融治疗后前列腺癌复发的评估

Evaluation of the TARGET score for MRI-based detection of prostate cancer recurrence in patients treated with HIFU hemiablation.
PubMed 文献 · Eur J Radiol · 2025-11-24

回顾性多中心研究纳入40例HIFU半消融后12个月行多参数MRI并穿刺活检的患者,三位放射科医师独立应用TARGET评分(治疗侧)和PI-RADS v2.1(未治疗侧)。TARGET对临床显著前列腺癌的敏感度60-100%、NPV 91-100%,但特异度54-69%、PPV 16-27%,AUC 0.57-0.79,读者间一致性中等(к=0.60-0.64)。作者认为TARGET的高NPV提示其可能排除临床显著前列腺癌,但敏感度和特异度中等、PPV低及一致性中等提示其可靠性有限,样本量小限制外推性。

要点

  • TARGET评分对临床显著前列腺癌的NPV达91-100%,可能用于排除复发。
  • 以≥3分为阈值时,TARGET敏感度60-100%,但特异度54-69%、PPV 16-27%。
  • TARGET读者间一致性中等(к=0.60-0.64),PI-RADS为к=0.54-0.55。

核心结论

  • TARGET评分的优势在于高NPV,提示其可能排除临床显著前列腺癌;但敏感度和特异度中等、PPV低及读者间一致性中等,提示TARGET一致识别临床显著前列腺癌复发的可靠性有限;样本量小限制结果的外推性。

研究设计与样本

  • 回顾性多中心研究,纳入40例接受HIFU半消融治疗局限性前列腺癌后12个月行随访多参数MRI并随后穿刺活检(参考标准)的患者,三位放射科医师独立评估TARGET评分(治疗侧)和PI-RADS v2.1(未治疗侧)。

诊断标准与关键数值

  • 40例患者中23例活检证实复发前列腺癌,共26个病灶,其中7个为临床显著前列腺癌(5/7位于治疗侧);以评分≥3为阈值,TARGET检测临床显著前列腺癌的敏感度60-100%(读者1-3)、NPV 91-100%、特异度54-69%、PPV 16-27%,AUC 0.57-0.79;检测任何前列腺癌的AUC 0.54-0.64;PI-RADS检测任何/临床显著前列腺癌的AUC 0.52-0.60(未治疗侧);读者间一致性TARGET к=0.60-0.64、PI-RADS к=0.54-0.55。

临床应用与阅片要点

  • 作者认为TARGET评分的高NPV提示其可能用于排除临床显著前列腺癌,但敏感度和特异度中等、PPV低及读者间一致性中等提示其一致识别临床显著前列腺癌复发的可靠性有限。

局限性

  • 总体样本量小限制研究结果的外推性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To evaluate diagnostic performance and inter-reader agreement of the Transatlantic Recommendations for Prostate Gland Evaluation with MRI after Focal Therapy (TARGET).

METHODS: This retrospective, multi-center study included patients who underwent high-intensity focused ultrasound (HIFU) hemiablation for localized prostate cancer (PCa), with follow-up multiparametric MRI (mpMRI) at 12 months and subsequent biopsy (reference standard). Three radiologists independently assessed the mpMRIs using the TARGET score (treated prostate side) and the PI-RADS score (v2.1, untreated side). Diagnostic performance metrics and area under the receiver operating characteristic curves (AUC) were computed for any-/clinically significant-PCa (cs-PCa) and two scoring thresholds (3 vs. 4). Inter-reader-agreement was analyzed using Fleiss к.

RESULTS: Of all 40 patients included, 23 had biopsy-proven recurrent PCa in 26 lesions, with seven lesions harboring cs-PCa (5/7 on the treated side). TARGET showed moderate to high sensitivity (Reader 1-3: 60-100 %), high NPV (91-100 %) but lower specificity (54-69 %) and PPV (16-27 %) in the detection of cs-PCa, given a scoring threshold of ≥ 3. The diagnostic performance for cs-PCa (AUC: 0.57-0.79) exceeded that of any-PCa (0.54-0.64). PI-RADS showed an overall moderate efficacy in any-/cs-PCa-detection (untreated prostate side, AUC: 0.52-0.60). Overall inter-reader agreement was moderate (TARGET к = 0.60-0.64, PI-RADS к = 0.54-0.55).

CONCLUSIONS: The strength of the TARGET score was its high NPV, implying its potential to rule out cs-PCa. However, the moderate sensitivity and specificity, low PPV and moderate inter-reader agreement indicate a limited reliability of TARGET to consistently identify cs-PCa recurrence. The generalizability of these findings is restricted by the overall small sample size.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Ehrengut C, Alberalar ND, Franz T, et al. Evaluation of the TARGET score for MRI-based detection of prostate cancer recurrence in patients treated with HIFU hemiablation. Eur J Radiol. 2025. PMID: 41319370. doi:10.1016/j.ejrad.2025.112572

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。